Limits of resistance testing

Antiviral Therapy

Volumn 5, Issue 1, 2000, Pages 71-76

  D'Aquila, Richard T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

CONFERENCE PAPER; DIAGNOSTIC VALUE; DRUG RESISTANCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; PRIORITY JOURNAL;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034060878     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Kemp SD, Shi C, Bloor S, Harrigan PR, J.W. M & Larder BA. 1998. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. Journal of Virology 1998; 72:5093-5098.
2. Nijhuis M, Schuurman R, de Jong D, van Leeuwen R, Lange J, Danne S, Keulen W, de Groot T & Boucher CA. Lamiyudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. Journal of Infectious Diseases, 1997; 176:398-405.
3. Whitcomb JM, Limoli K, Wrin T, Smith D, Tian H, Parkin N, Lie YS & Petropoulos CJ. Phenotypic and genotypic analysis of stavudine-resistant isolates of HIV-1. Antiviral Therapy 1998; 3 (Suppl. 1):14-15.
4. Bloor S, Hertogs K, Desmer RL, Pauwels R & Larder BA. Virological basis for HIV-1 resistance to stavudine investigated By analysis of clinical samples. Antiviral Therapy 1998; 3 (Suppl. 1):13-14.
5. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, Katzenstein DA & Merigan TC. A 6-base-pair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. Journal of Clinical Investigation 1998; 102:1769-75.